Correlation between serum cathepsin S and insulin resistance in type 2 diabetes
- Authors:
- Ruo-Ping Chen
- An Ren
- Shan-Dong Ye
View Affiliations
Affiliations: Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, P.R. China
- Published online on: September 9, 2013 https://doi.org/10.3892/etm.2013.1290
-
Pages:
1237-1242
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Cathepsin S (CatS), a proteolytic enzyme, which belongs to the cysteine proteinase family, is associated with atherosclerosis, coronary heart disease, cancer and other diseases. The present study aimed to explore the correlation between serum CatS and insulin resistance (IR) in patients with type 2 diabetes. A total of 51 patients with type 2 diabetes (Group DM) were recruited for this study and 49 healthy individuals were selected as normal controls (Group NC). Blood pressure and body mass index (BMI) were recorded, and serum creatinine, CatS, glycosylated hemoglobin (HbA1c), lipid and insulin levels, and fasting plasma glucose (FPG) levels were measured in all the participants. The homeostatic model assessment index of IR (HOMA-IR) was calculated according to FPG and serum insulin levels. Serum CatS, very low density lipoprotein (VLDL) and triglyceride (TG) levels in Group DM were significantly higher compared with those in Group NC (P=0.000, 0.014 and 0.020, respectively). Significantly positive correlations were identified between CatS levels and VLDL and TG levels, respectively (P<0.05 for both); however, no significant correlations were determined between CatS levels and age, course of disease, blood pressure, cholesterol, BMI, FPG, HbAc1 and HOMA-IR (P>0.05). Further stratification analysis showed that CatS had no association with IR at different HOMA-IR and HbA1c levels. The present study demonstrated that serum CatS, which was significantly increased in patients with type 2 diabetes, had no correlation with IR. This indicates that CatS and IR are independent of each other; however, the precise mechanisms require further investigation.
View References
|
1.
|
Reaven GM: Banting lecture 1988. Role of
insulin resistance in human disease. Diabetes. 37:1595–1607. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Zimmet PZ, McCarty DJ and de Courten MP:
The global epidemiology of non-insulin-dependent diabetes mellitus
and the metabolic syndrome. J Diabetes Complications. 11:60–68.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Hanefeld M and Scriba P: Metabolic
syndrome. Internist (Berl). 37:679–680. 1996.
|
|
4.
|
Clark AK, Wodarski R, Guida F, Sasso O and
Malcangio M: Cathepsin S release from primary cultured microglia is
regulated by the P2X7 receptor. Glia. 58:1710–1726. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Sukhova GK, Shi GP, Simon DI, et al:
Expression of the elastolytic cathepsins S and K in human atheroma
and regulation of their production in smooth muscle cells. J Clin
Invest. 102:576–583. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Burns-Kurtis CL, Olzinski AR, Needle S, et
al: Cathepsin S expression is up-regulated following balloon
angioplasty in the hypercholesterolemic rabbit. Cardiovasc Res.
62:610–620. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Sukhova GK, Zhang Y, Pan JH, et al:
Efficiency of cathepsin S reduces atherosclerosis in LDL
receptor-deficient mice. J Clin Invest. 111:897–906. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Rodgers KJ, Watkins DJ, Miller AL, et al:
Destabilizing role of cathepsin S in murine atherosclerotic
plaques. Arterioscler Thromb Vasc Biol. 26:851–856. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Gu FF, Lü SZ, Chen YD, et al: Relationship
between plasma cathepsin S and cystatin C levels and coronary
plaque morphology of mild to moderate lesions: An in vivo study
using intravascular ultrasound. Chin Med J (Engl). 122:2820–2826.
2009.
|
|
10.
|
Li X, Wu K, Edman M, Schenke-Layland K, et
al: Increased expression of cathepsins and obesity-induced
proinflammatory cytokines in lacrimal glands of male NOD mouse.
Invest Ophthalmol Vis Sci. 51:5019–5029. 2010. View Article : Google Scholar
|
|
11.
|
Tominaga M: Diagnostic criteria for
diabetes mellitus. Rinsho Byori. 47:901–908. 1999.(In
Japanese).
|
|
12.
|
Hsing LC, Kirk EA, McMillen TS, et al:
Roles for cathepsins S, L, and B in insulitis and diabetes in the
NOD mouse. J Autoimmun. 34:96–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Liu J, Ma L, Yang J, et al: Increased
serum cathepsin S in patients with atherosclerosis and diabetes.
Atherosclerosis. 186:411–419. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Liu L, Zhang Y, Chen N, et al:
Upregulation of myocellular DGAT1 augments triglyceride synthesis
in skeletal muscle and protects against fat-induced insulin
resistance. J Clin Invest. 117:1679–1689. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Ye S, Zheng M, Hu Y, et al: Hydrochloride
pioglitazone decreases urinary monocyte chemoattractant protein-1
excretion in type 2 diabetics. Diabetes Res Clin Pract. 88:247–251.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Jobs E, Risérus U, Ingelsson E, et al:
Serum cathepsin S is associated with serum C-reactive protein and
interleukin-6 independently of obesity in elderly men. J Clin
Endocrinol Metab. 95:4460–4464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Naour N, Rouault C, Fellahi S, et al:
Cathepsins in human obesity: Changes in energy balance
predominantly affect cathepsin s in adipose tissue and in
circulation. J Clin Endocrinol Metab. 95:1861–1868. 2010.
View Article : Google Scholar : PubMed/NCBI
|
